Scholarlink

Background <p>Glioblastoma is a highly aggressive primary brain malignancy characterized by poor median survival despite trimodal therapy. While established prognostic factors exist, significant heterogeneity in patient outcomes persist. This study aims to evaluate whether white-cell differentials predict oncologic outcomes in glioblastoma (GBM).</p> Methods <p>We retrospectively analyzed 85 GBM patients treated with standard surgery, radiotherapy (60&#xa0;Gy in 30 fractions), and temozolomide. Clinical data (age, Karnofsky performance status, extent of resection, MGMT methylation, corticosteroid use, dosimetric data) and hematologic indices (absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), absolute eosinophil (AEC) and basophil counts, etc.) were collected at baseline and up to 3 months post-chemoradiation.</p> Results <p>Median overall survival (OS) in our cohort was 22.5 months (95% CI, 20.4–32.2). On univariate analysis, higher AEC correlated with improved OS at baseline (HR 0.68; <i>p</i> = 0.013) and at 2 months (HR 0.58; <i>p</i> = 0.019). In the combined multivariable model—controlling for age, extent of resection, MGMT status, KPS, steroid use, and % of brain volume receiving 60&#xa0;Gy) —baseline AEC remained independently prognostic (aHR 0.64; <i>p</i> = 0.021).</p> Conclusions <p>Baseline eosinophils were independently associated with improved survival. Such findings highlight the importance of host immunity and baseline eosinophils as a potential prognostic marker of OS in GBM and warrant larger, prospective studies on prognostic marker validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Eric Giannaris,
  • Geoffrey Sedor,
  • Catherine S. Spina,
  • Kristin Hsieh,
  • Carl Elliston,
  • Simon K. Cheng,
  • Fabio M. Iwamoto,
  • Guy M. McKhann,
  • Michael B. Sisti,
  • Jeffrey N. Bruce,
  • Tony J. C. Wang,
  • Matthew Gallitto

摘要

Background

Glioblastoma is a highly aggressive primary brain malignancy characterized by poor median survival despite trimodal therapy. While established prognostic factors exist, significant heterogeneity in patient outcomes persist. This study aims to evaluate whether white-cell differentials predict oncologic outcomes in glioblastoma (GBM).

Methods

We retrospectively analyzed 85 GBM patients treated with standard surgery, radiotherapy (60 Gy in 30 fractions), and temozolomide. Clinical data (age, Karnofsky performance status, extent of resection, MGMT methylation, corticosteroid use, dosimetric data) and hematologic indices (absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), absolute eosinophil (AEC) and basophil counts, etc.) were collected at baseline and up to 3 months post-chemoradiation.

Results

Median overall survival (OS) in our cohort was 22.5 months (95% CI, 20.4–32.2). On univariate analysis, higher AEC correlated with improved OS at baseline (HR 0.68; p = 0.013) and at 2 months (HR 0.58; p = 0.019). In the combined multivariable model—controlling for age, extent of resection, MGMT status, KPS, steroid use, and % of brain volume receiving 60 Gy) —baseline AEC remained independently prognostic (aHR 0.64; p = 0.021).

Conclusions

Baseline eosinophils were independently associated with improved survival. Such findings highlight the importance of host immunity and baseline eosinophils as a potential prognostic marker of OS in GBM and warrant larger, prospective studies on prognostic marker validation.